Breaking News Instant updates and real-time market news.

BMRN

BioMarin

$88.36

-0.64 (-0.72%)

06:39
11/29/16
11/29
06:39
11/29/16
06:39

BioMarin downgraded to Equal Weight from Overweight at Barclays

Barclays analyst Geoff Meacham downgraded BioMarin to Equal Weight and lowered its price target to $105 from $125. The analyst said moderating growth and lack of 2017 catalysts provide only modest upside opportunity over the next 12 months.

  • 02

    Dec

  • 03

    Dec

  • 07

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

BMRN BioMarin
$88.36

-0.64 (-0.72%)

11/07/16
PIPR
11/07/16
UPGRADE
Target $335
PIPR
Overweight
Biogen upgraded to Overweight from Neutral at Piper Jaffray
In a research note partially titled "We Hope We Don't Regret This," Piper Jaffray analyst Joshua Schimmer upgraded Biogen (BIIB) to Overweight with an unchanged price target of $335. The company still has time to "get its act together to maximize the value of its SMA franchise, and stop being M&A disciplined/pipeline-undisciplined," Schimmer tells investors in a research note. He believes the valuation is "reasonable" for the Alzheimer's and SMA franchises as well as some "interesting" pipeline opportunities. Schimmer this morning also downgraded BioMarin (BMRN) to Neutral.
11/07/16
11/07/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. BioMarin (BMRN) downgraded to Neutral from Overweight at Piper Jaffray with analyst Joshua Schimmer saying he sees a "number of under-appreciated" risks ahead. 2. Akorn (AKRX) downgraded to Underperform from Buy at BofA/Merrill and to Hold from Buy at WallachBeth. 3. GoPro (GPRO) downgraded to Underperform from Neutral at BofA/Merrill. 4. L Brands (LB) downgraded to Underperform from Hold at Jefferies with analyst Randal Konik citing rising competition and pricing competition. 5. Xerox (XRX) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Brian Essex saying both the BPO and DocTech businesses are facing secular pressures and said the Conduent spinco will add $2B of net incremental leverage and faces headwinds in both growth and pricing and will need to focus on margin expansion to drive shareholder value. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, cllick here.
11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Biotech stocks should be bought on post-election decline, says RBC Capital
RBC Capital recommends buying biotech stocks today on weakness. The firm notes that stocks usually rebound after they drop due to political events that don't affect their fundamentals, and it believes that the decline in biotech stocks today is in that category. The firm says that President-elect Trump probably won't focus on drug prices or Medicare reform. It adds that biotech companies should benefit from the fact that Congress will stay in GOP hands and the apparent failure of California's Proposition 61 initiative. The firm identifies Celgene (CELG), Biogen (BIIB), Vertex (VRTX), BioMarin (BMRN), and Prothena (PRTA) as its favorite names in the sector.
11/18/16
GABE
11/18/16
NO CHANGE
Target $99
GABE
Buy
Incyte, Regeneron among Gilead M&A options after latest setback, says Gabelli
Gabelli analyst Jing He noted Gilead's (GILD) "mixed" results from its Phase III trials evaluating momelotinib, which showed that the drug is not superior to Incyte's (INCY) Jakafi. Commenting on Gilead's potential path after momelotinib's "disappointing" results and several other pipeline setbacks this year, He suggested that Gilead could look to buy Incyte, which looks like "Regeneron lite," or simply buy Regeneron (REGN) itself. The analyst said Gilead could alternately target an orphan drug company such as Alexion (ALXN), Vertex (VRTX) or BioMarin (BMRN). She keeps a Buy rating and $99 per share private market value on Gilead shares, as she expects M&A to be a catalyst for the stock.

TODAY'S FREE FLY STORIES

CAA

CalAtlantic

, LEN

Lennar

09:23
01/22/18
01/22
09:23
01/22/18
09:23
Recommendations
CalAtlantic, Lennar analyst commentary  »

CalAtlantic price target…

CAA

CalAtlantic

LEN

Lennar

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJI

South Jersey Industries

09:21
01/22/18
01/22
09:21
01/22/18
09:21
Downgrade
South Jersey Industries rating change  »

South Jersey Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

KBH

KB Home

09:20
01/22/18
01/22
09:20
01/22/18
09:20
Recommendations
KB Home analyst commentary  »

KB Home price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

09:20
01/22/18
01/22
09:20
01/22/18
09:20
General news
U.S. Producer Sentiment Tailwinds Extend Into 2018: »

U.S. Producer Sentiment…

TOL

Toll Brothers

09:19
01/22/18
01/22
09:19
01/22/18
09:19
Recommendations
Toll Brothers analyst commentary  »

Toll Brothers price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$179.64

4.16 (2.37%)

, HAL

Halliburton

09:19
01/22/18
01/22
09:19
01/22/18
09:19
Hot Stocks
On The Fly: Pre-market Movers »

UP AFTER EARNINGS: Wynn…

WYNN

Wynn Resorts

$179.64

4.16 (2.37%)

HAL

Halliburton

PETS

PetMed Express

$53.24

2.67 (5.28%)

OPB

Opus Bank

$28.70

0.05 (0.17%)

BCRX

BioCryst

$5.59

-0.09 (-1.58%)

IDRA

Idera Pharmaceuticals

$2.55

0.145 (6.03%)

ANF

Abercrombie & Fitch

AAPL

Apple

$178.46

-0.8 (-0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 01

    Feb

CYTX

Cytori Therapeutics

$0.40

-0.0188 (-4.48%)

09:19
01/22/18
01/22
09:19
01/22/18
09:19
Hot Stocks
Cytori Therapeutics completes enrollment in Habeo trial for scleroderma »

Cytori Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBS

UBS

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Periodicals
UBS to start moving jobs in early 2018 ahead of Brexit, Telegraph reports »

UBS will begin shifting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Hot Stocks
Breaking Hot Stocks news story on Halliburton »

Halliburton says expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

PHM

PulteGroup

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Recommendations
PulteGroup analyst commentary  »

PulteGroup price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

RF

Regions Financial

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Upgrade
Regions Financial rating change  »

Regions Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Options
Overnight activity included 111 trades in SPX and 29 trades in VIX »

111 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RF

Regions Financial

09:17
01/22/18
01/22
09:17
01/22/18
09:17
Upgrade
Regions Financial rating change  »

Regions Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

09:16
01/22/18
01/22
09:16
01/22/18
09:16
Recommendations
D.R. Horton analyst commentary  »

D.R. Horton price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

SDR

SandRidge Mississippian Trust II

09:16
01/22/18
01/22
09:16
01/22/18
09:16
Hot Stocks
SandRidge Mississippian Trust II receives NYSE notice on listing standards »

SandRidge Mississippian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:15
01/22/18
01/22
09:15
01/22/18
09:15
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

HAL

Halliburton

09:14
01/22/18
01/22
09:14
01/22/18
09:14
Hot Stocks
Halliburton says expects improved utilization to drive margin growth »

Sees boosting frack…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

FE

FirstEnergy

09:14
01/22/18
01/22
09:14
01/22/18
09:14
Hot Stocks
FirstEnergy receives $2.5B equity investment »

FirstEnergy announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

DNKN

Dunkin' Brands

$64.56

-0.53 (-0.81%)

09:13
01/22/18
01/22
09:13
01/22/18
09:13
Upgrade
Dunkin' Brands rating change  »

William Blair upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VC

Visteon

$131.85

-0.54 (-0.41%)

09:13
01/22/18
01/22
09:13
01/22/18
09:13
Recommendations
Visteon analyst commentary  »

Visteon price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNX

Mellanox

$65.75

0.65 (1.00%)

09:12
01/22/18
01/22
09:12
01/22/18
09:12
Conference/Events
Mellanox management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

IOVA

Iovance Biotherapeutics

$10.70

1.075 (11.17%)

09:12
01/22/18
01/22
09:12
01/22/18
09:12
Recommendations
Iovance Biotherapeutics analyst commentary  »

Iovance Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

09:11
01/22/18
01/22
09:11
01/22/18
09:11
Hot Stocks
Halliburton says International business started to recover in 2H17 »

Comments from Q4 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

09:10
01/22/18
01/22
09:10
01/22/18
09:10
General news
Treasury Option Action: doubly bullish positioning »

Treasury Option Action:…

GRA

W.R. Grace

$73.71

0.92 (1.26%)

09:09
01/22/18
01/22
09:09
01/22/18
09:09
Hot Stocks
W.R. Grace licenses UNIPOL PP process technology to Poland's Grupa Azoty »

W. R. Grace has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 02

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.